Consumer Site

Resources

Resources for Your Patients
doctor discussion guide for adults 18 plus

Deplin FC™ Patient Discussion Guide (Adults)

This guide can help you and your patient discuss their depression symptoms, treatment, and whether Deplin FC™ is right for them.

Download
Doctor discussion guide for adolescent patients.

Deplin FC™ Patient Discussion Guide (Adolescents)

This guide can help you and your patient discuss their depression symptoms, treatment, and whether Deplin FC™ is right for them.

Download
Deplin FC depression care program flyer with a timeline and promotional text.

Deplin FC™ Journey Infographic

This infographic can help patients understand what to expect and reassure them on their depression care journey with Deplin FC™.

Download
Deplin symptom tracker form for patients aged 18 years and older, with a purple and white color scheme.

Symptom Tracker (Adults)

Patients can track their symptoms each month and discuss them with you to assess their progress with their prescribed DEPLIN® product.

Download
Deplin Symptom tracker for adolescents aged 12 and older with a white background

Symptom Tracker (Adolescents)

Patients can track their symptoms each month and discuss them with you to assess their progress with their prescribed DEPLIN® product.

Download

Mechanism of Action Videos

Addressing Unmet Needs: The Role of Folate in MDD Part 1

Watch Video

Addressing Unmet Needs: The Role of Folate in MDD Part 2

Watch Video
More Resources
Become a Prescriber

Deplin FC™ is a medical food specially formulated to meet the distinctive nutritional requirements for neurotransmitter imbalances in the clinical dietary management of depression and schizophrenia. Use under medical supervision.

DeplinPRO Mood Health™ is a medical food specially formulated to meet the distinctive nutritional requirements for neurotransmitter imbalances in the clinical dietary management of mood disorders. Use under medical supervision.

†Deplin FC™ (FC for “free & clear”) and DeplinPRO Mood Health™are free from major allergens: milk, eggs, fish or shellfish, sesame, tree nuts, peanuts, wheat, and soy.

*Based on US dollar sales through IQVIA NSP reporting channels from January 2023 – December 2024 of Deplin® branded medical foods compared to other branded medical foods indicated for depression.

§Actual testimonials but pictures and names are for illustrative purposes only.

  1. Liwinski T, Lang UE. Nutrients. 2023;15(17):3859.
  2. Mrozek W, et al. Nutrition. 2023:112143.
  3. Shelton RC, et al. Primary Care Companion for CNS Disorders. 2013;15:1-9.
  4. Martami F, et al. Nutrients. 2023;15:3952.
  5. Piao M, et al. Neuropsychiatry (London). 2017;7:378-386.
  6. Anglin RE. The British Journal of Psychiatry. 2013;202:100-107.
  7. Berridge MJ. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 2016;371:20150434.
  8. Yosaee S, et al. General Hospital Psychiatry. 2022;74:110- 117.
  9. Li MY, et al. Frontiers in Nutrition. 2022;9:853846. (original 34)
  10. Hidese S, et al. Nutrients. 2019;11:2362.
  11. Lehrer MH, et al. Psychoneuroendocrinology. 2020;113:104510.
  12. Roffman LJ, et al. Molecular Psychiatry. 2018;23:316-322.
  13. Mikola T, et al. Critical Reviews in Food Science and Nutrition. 2023;63(33):11784-11801.
  14. Andrews PW, et al. Frontiers in Psychology, 2012;24:117.
  15. Bender A, et al. Journal of Psychiatric Research. 2017;95:9-18.
  16. Li Z, et al. Journal of Affective Disorders. 2018;228:68-74. (original 44)
  17. Maxfield L, et al. Zinc deficiency. In: StatPearls [Internet]. StatPearls Publishing. 2023. https://www.ncbi.nlm.nih.gov/books/NBK493231/. Accessed October 21, 2025.
  18. Jain R, et al. CNS Spectrums. 2020;25(6):750-764.
  19. Wang JT, et al. Lancet. 2010;376(9736):180-188.
  20. Medline. Vitamin D deficiency. https://medlineplus.gov/vitaminddeficiency.html?utm_source=mplusconnect&utm_medium=application. Accessed October 21, 2025.
  21. Abdollahi S, et al. Advances in Nutrition. 2020;11:398-411
  22. Medline. Folate deficiency. https://medlineplus.gov/ency/article/000354.htm. Accessed October 21, 2025.
  23. Araujo JR, et al. Ageing Research Reviews. 2015;22:9-19.
  24. Gibson A, et al. QJM: Monthly Journal of the Association of Physicians. 2008;101(11):881-887.
  25. Wijnia JW, et al. Alcoholism: Clinical and Experimental Research. 2013;37(S1):E209-E215.
  26. Shere M, et al. Journal of Obstetrics and Gynaecology Canada. 2015;37(5):430-438.
  27. Huang HL, et al. Biomedical Reports. 2016;5:413-416.
  28. Wulffele MG, et al. Journal of Internal Medicine. 2003;254:455-463.
  29. Papakostas G, et al. Am J Psychiatry. 2012;169:1267-1274.
  30. Yosaee S, et al. Nutrition. 2020;71:110601.
  31. Evans M, et al. Neurology and Therapy. 2021;10:1061-1078.
  32. Zajecka JM, et al. Journal of Clinical Psychiatry. 2016;77(5):654-660.
  33. Wang T, et al. Evidence-Based Practice in Child and Adolescent Mental Health. 2024;9(1):119-137.(original 39)
  34. Ghaseminejad-Raeini A, et al. Frontiers in Immunology. 2023;14:950465.
  35. Krajewska M, et al. Frontiers in Endocrinology. 2022;13:920340.
  36. Hoepner CT, et al. Nutrients. 2021;13:767.
  37. Sun R, et al. Biomolecules. 2022;12:1000
  38. Miodownik C, et al. Clinical Neuropharmacology. 2011:34(4):155-160.
  39. Sakamato FL, et al. Pharmacological Research. 2019;147:104395.
  40. Qiu W, et al. Journal of Neuroendocrinology. 2019;31(10):e12787.
  41. Gammoh OS, Bashatwah R. Electronic Journal of General Medicine. 2023;20(5):em513.
  42. Szalach LP, et al. Archivum Immunologiae et Therapiae Experimentalis. 2019;67:143-151.
  43. Willems FF, et al. British Journal of Pharmacology. 2004;141:825-830.
  44. Kaviani M, et al. Journal of Affective Disorders. 2020;269:28-35.
  45. Finn R. Innophos. Chelamax® Zinc Bisglycinate: A Superior Alternative to Traditional Zinc. Solubility Whitepaper.
  46. Finn R. Innophos. Chelamax®: Chelated Minerals Show Increased Absorption. Absorption Whitepaper.
  47. Ranjbar E, et al. Nutritional Neuroscience. 2014;17(2):65-71.